

October 17, 2023

Dear Ms. Tom,

Thank you for reaching out to the ASTS to follow up on our supply chain concerns regarding organ preservation solution. We have solicited input from our members on this issue, and our answers can be found below:

1. Have you seen any changes in demand for organ preservation solutions over the past year?

Our members have not encountered the same challenges in obtaining organ preservation solution as they did during the COVID-19 pandemic. However, they noted that transplant volume has continued to increase, so presumably the demand for organ preservation solution is *also increasing*.

- a. If so, have you seen any concerns or challenges in meeting customer demand?
  Some OPOs have put caps on the amount of fluid we can use at each
  - case.
- What specific types of organ preservation solutions are affected (e.g., UW, HTK, etc.)?
  In cases where limited by the OPO, it is mostly UW and HTK.
- 2. Have you seen any changes in demand for cannulas and tubing used to port the solution into the organ?

Our members have not encountered the same challenges in obtaining cannulas and tubing used to port the solution into the organ as they did during the COVID-19 pandemic. However, they noted that transplant volume has continued to increase, so presumably the demand for organ preservation solution is also increasing.

- a. If so, have you seen any concerns or challenges in meeting customer demand?
  - No specific concerns or challenges.
- Which types of cannulas (e.g., kidney perfusion) and sizes (e.g., 12 F) are impacted?
  No specific concerns or challenges.

3. Are there forecasted trends in organ procurements, such as seasonal changes, that may impact demand for organ preservation solutions? We do not see a way to forward forecast the season variation in organ procurement, but it is safe to say that there are more donors, and more donors being pursued. In this context, solutions and the associated equipment are in greater demand. We anticipate increases in overall transplant volume for the next five years based on market projections.

## **President** Elizabeth A. Pomfret, MD, PhD University of Colorado

President-Elect Ginny L. Bumgardner, MD, PhD The Ohio State University

Secretary Debra L. Sudan, MD Duke University Medical Center

**Treasurer** James F. Markmann, MD, PhD Harvard Medical School

**DEI Officer** Henry B. Randall, MD, MBA SSM Health Saint Louis University

Immediate Past President William C. Chapman, MD Washington University

**Past President** A. Osama Gaber, MD Houston Methodist Hospital

## Councilors-at-Large

Linda C. Cendales, MD Ty B. Dunn, MD, MS Jayme E. Locke, MD, MPH André A. S. Dick, MD Majella B. Doyle, MD, MBA Sunil K. Geevarghese, MD, MSCI Daniela P. Ladner, MD, MPH Matthew H. Levine, MD, PhD Dinee C. Simpson, MD Samantha J. Halpern, MSN, CRNP

**Executive Director** Maggie Kebler-Bullock, CFRE

## **National Office**

1401 S. Clark St. Suite 1120 Arlington, VA 22202 703-414-7870 asts@asts.org ASTS.org

American Transplant Congress June 1–5, 2024 Philadelphia, Pennsylvania

## 4. Is there any additional information related to this topic that you can share? N/A

If you have any additional questions, please do not hesitate to contact ASTS Associate Director, Advocacy, Emily Besser, MA, CAE, at <u>Emily.Besser@asts.org</u>.

Sincerely,

Epure A. Pomper

Elizabeth A. Pomfret, MD, PhD, FACS President